Research progress on extrahepatic targeted delivery of mRNA-LNP
10.16438/j.0513-4870.2024-0916
- VernacularTitle:mRNA-LNP肝外靶向递送的研究进展
- Author:
Lei LI
1
,
2
;
Cai-li ZHAO
3
;
Ning ZHANG
3
;
Chun-lei LI
1
,
2
Author Information
1. School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China
2. Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group, Shijiazhuang 050035, China
3. Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group, Shijiazhuang 050035, China
- Publication Type:Research Article
- Keywords:
targeted delivery;
messenger ribonucleic acid;
lipid nanoparticle;
endogenous targeting;
ligand modification
- From:
Acta Pharmaceutica Sinica
2025;60(2):359-368
- CountryChina
- Language:Chinese
-
Abstract:
Messenger ribonucleic acid (mRNA) is a promising therapeutic drug with great potential in the fields of immunology, oncology, vaccines and inborn metabolic diseases. However, due to its instability and susceptibility to nuclease degradation, efficient delivery vectors are required. Lipid nanoparticles (LNPs) are recognized as the most mature delivery vectors due to their advantages of easy formulation, high stability, efficient cell uptake and endosomal escape. However, the accumulation of LNPs in the liver severely limits the targeting and treatment of mRNA-LNP technology beyond the liver. To overcome this obstacle, researchers have been focusing on various means to achieve precise delivery of extrahepatic tissues and organs. This article mainly expounds the research progress of LNP-specific delivery mRNA from three aspects: endogenous targeting, active targeting and selection of administration route, in order to provide ideas and directions for the design of new mRNA-LNP delivery systems in the future.
